CXCL13 and lung cancer: Hanada et al. proposed a phenotypic signature for detecting neoantigen‐reactive T cells in lung cancer, by integrating clonotype frequency, CD39 protein expression, and CXCL13 mRNA levels through advanced multi‐omics approaches including TCR sequencing and CITE‐seq (cellular indexing of transcriptomes and epitopes by sequencing).[89] Supporting these findings, Liu et al.